MA56183A - Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b - Google Patents
Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2bInfo
- Publication number
- MA56183A MA56183A MA056183A MA56183A MA56183A MA 56183 A MA56183 A MA 56183A MA 056183 A MA056183 A MA 056183A MA 56183 A MA56183 A MA 56183A MA 56183 A MA56183 A MA 56183A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- pyridines
- receptor modulators
- substituted heteroaromatic
- glun2b receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861665P | 2019-06-14 | 2019-06-14 | |
PK34920 | 2020-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56183A true MA56183A (fr) | 2022-04-20 |
Family
ID=73781827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056183A MA56183A (fr) | 2019-06-14 | 2020-06-12 | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
Country Status (21)
Country | Link |
---|---|
US (2) | US11530210B2 (fr) |
EP (1) | EP3982958A1 (fr) |
JP (1) | JP2022536424A (fr) |
KR (1) | KR20220024512A (fr) |
CN (1) | CN114007610A (fr) |
AU (1) | AU2020291188A1 (fr) |
BR (1) | BR112021025141A2 (fr) |
CA (1) | CA3143276A1 (fr) |
CL (1) | CL2021003257A1 (fr) |
CO (1) | CO2021016860A2 (fr) |
CR (1) | CR20210615A (fr) |
DO (1) | DOP2021000250A (fr) |
EC (1) | ECSP21090450A (fr) |
IL (1) | IL288858A (fr) |
JO (1) | JOP20210330A1 (fr) |
MA (1) | MA56183A (fr) |
MX (1) | MX2021015503A (fr) |
PE (1) | PE20220806A1 (fr) |
SG (1) | SG11202112405VA (fr) |
TW (1) | TW202115054A (fr) |
WO (1) | WO2020249785A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
EP3983413A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
MX2021015506A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. |
CA3143276A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyridines heteroaromatiques substituees et leur utilisation en tant que modulateurs du recepteur glun2b |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
CA3143102A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo[4,3-b]pyridines substituees et leur utilisation en tant que modulateurs du recepteur glun2b |
BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
CN114149425A (zh) * | 2021-11-16 | 2022-03-08 | 上海应用技术大学 | 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
US6251897B1 (en) | 1996-07-31 | 2001-06-26 | Nikken Chemicals Co., Ltd | 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same |
WO2002000629A1 (fr) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Antagonistes des recepteurs nmda nr2b de l'iminopyrimidine |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
AU2002324283B2 (en) | 2001-07-24 | 2008-02-21 | Serono Genetics Institute S.A. | Variants and exons of the GlyT1 transporter |
CN100368411C (zh) | 2002-03-28 | 2008-02-13 | 卫材R&D管理有限公司 | 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物 |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
AR047744A1 (es) | 2004-02-18 | 2006-02-15 | Nps Pharma Inc | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico |
CA2581623A1 (fr) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Composes a base de pyridine, leur procede de preparation et compositions les contenant |
US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
WO2008145616A1 (fr) | 2007-05-25 | 2008-12-04 | Abbott Gmbh & Co. Kg | Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2) |
WO2009004430A1 (fr) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate |
EP2194045A4 (fr) | 2007-08-30 | 2011-09-21 | Takeda Pharmaceutical | Dérivé de pyrazole substitué |
EP2215073A4 (fr) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | Modulation du sommeil avec des antagonistes du récepteur nr2b |
JP2011516417A (ja) | 2008-03-27 | 2011-05-26 | エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Nmdanr2b−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
WO2009157196A1 (fr) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | Composé amide |
BRPI0917540A2 (pt) | 2008-08-05 | 2015-11-17 | Daiichi Sankyo Co Ltd | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
WO2010108187A2 (fr) | 2009-03-20 | 2010-09-23 | Brandeis University | Composés et procédés pour traiter les infections microbiennes gastro-intestinales mammaliennes |
WO2011022348A1 (fr) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Modulateurs d'éthylène diamine d'une amide hydrolase d'acide gras |
US8765784B2 (en) | 2010-06-09 | 2014-07-01 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
EP2669270B1 (fr) | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Composés apparentés à l'indole en tant qu'inhibiteurs d'urat1 |
JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
SI2570415T1 (sl) | 2011-09-19 | 2015-12-31 | Sanofi | N-(4-(1H-pirazolo(3,4-b)pirazin-6-il-fenil)-sulfonamidi in njihova uporaba kot zdravila |
WO2013060029A1 (fr) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Modulateurs allostériques des récepteurs métabotropiques du glutamate |
WO2013130855A1 (fr) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Dérivés d'indazole |
MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
US9650358B2 (en) | 2013-03-13 | 2017-05-16 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
CA2903293C (fr) | 2013-03-15 | 2020-10-13 | Plexxikon Inc. | Composes heterocycliques et leurs utilisations |
KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
MX367085B (es) | 2013-07-31 | 2019-08-05 | Merck Patent Gmbh | Piridinas, pirimidinas y pirazinas como inhibidores de tirosina cinasa de bruton e inhibidores y usos de las mismas. |
ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
CN107567452B (zh) * | 2015-04-29 | 2020-07-07 | 詹森药业有限公司 | 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途 |
CA2991765C (fr) * | 2015-07-09 | 2023-10-03 | Janssen Pharmaceutica Nv | 4-azaindoles substitues et leur utilisation comme modulateurs du recepteur de glun2b |
AU2017217542B2 (en) | 2016-02-10 | 2021-06-03 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
TW201819376A (zh) * | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating S1P1 activity and methods of using them |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
EP3774732A4 (fr) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
CA3143102A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo[4,3-b]pyridines substituees et leur utilisation en tant que modulateurs du recepteur glun2b |
CA3143276A1 (fr) * | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyridines heteroaromatiques substituees et leur utilisation en tant que modulateurs du recepteur glun2b |
EP3983413A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
MX2021015506A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
-
2020
- 2020-06-12 CA CA3143276A patent/CA3143276A1/fr active Pending
- 2020-06-12 CR CR20210615A patent/CR20210615A/es unknown
- 2020-06-12 WO PCT/EP2020/066384 patent/WO2020249785A1/fr unknown
- 2020-06-12 MA MA056183A patent/MA56183A/fr unknown
- 2020-06-12 PE PE2021002072A patent/PE20220806A1/es unknown
- 2020-06-12 CN CN202080043611.8A patent/CN114007610A/zh active Pending
- 2020-06-12 JP JP2021573899A patent/JP2022536424A/ja active Pending
- 2020-06-12 JO JOP/2021/0330A patent/JOP20210330A1/ar unknown
- 2020-06-12 TW TW109119836A patent/TW202115054A/zh unknown
- 2020-06-12 KR KR1020227001097A patent/KR20220024512A/ko unknown
- 2020-06-12 AU AU2020291188A patent/AU2020291188A1/en active Pending
- 2020-06-12 US US16/899,829 patent/US11530210B2/en active Active
- 2020-06-12 SG SG11202112405VA patent/SG11202112405VA/en unknown
- 2020-06-12 EP EP20733713.0A patent/EP3982958A1/fr active Pending
- 2020-06-12 BR BR112021025141A patent/BR112021025141A2/pt unknown
- 2020-06-12 MX MX2021015503A patent/MX2021015503A/es unknown
-
2021
- 2021-12-02 DO DO2021000250A patent/DOP2021000250A/es unknown
- 2021-12-07 CL CL2021003257A patent/CL2021003257A1/es unknown
- 2021-12-09 IL IL288858A patent/IL288858A/en unknown
- 2021-12-13 CO CONC2021/0016860A patent/CO2021016860A2/es unknown
- 2021-12-14 EC ECSENADI202190450A patent/ECSP21090450A/es unknown
-
2022
- 2022-09-12 US US17/942,829 patent/US20230045960A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220024512A (ko) | 2022-03-03 |
JP2022536424A (ja) | 2022-08-16 |
CO2021016860A2 (es) | 2022-01-17 |
PE20220806A1 (es) | 2022-05-20 |
CR20210615A (es) | 2022-01-31 |
AU2020291188A1 (en) | 2022-01-20 |
CL2021003257A1 (es) | 2022-08-19 |
US11530210B2 (en) | 2022-12-20 |
TW202115054A (zh) | 2021-04-16 |
DOP2021000250A (es) | 2022-03-31 |
JOP20210330A1 (ar) | 2023-01-30 |
MX2021015503A (es) | 2022-04-20 |
US20230045960A1 (en) | 2023-02-16 |
WO2020249785A1 (fr) | 2020-12-17 |
EP3982958A1 (fr) | 2022-04-20 |
IL288858A (en) | 2022-02-01 |
ECSP21090450A (es) | 2022-01-31 |
BR112021025141A2 (pt) | 2022-01-25 |
CN114007610A (zh) | 2022-02-01 |
US20210017169A1 (en) | 2021-01-21 |
SG11202112405VA (en) | 2021-12-30 |
CA3143276A1 (fr) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56183A (fr) | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
MA56196A (fr) | Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b | |
MA52244A (fr) | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
MA44075A (fr) | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 | |
MA49753A (fr) | Agents de liaison se liant à pd-l1 et cd137 et leur utilisation | |
MA50502A (fr) | Adénovirus et utilisations associées | |
DK3743406T3 (da) | Tmem16a modulatorer | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
ES2821790T8 (es) | Moduladores de la vía de estrés integrada | |
DK3490565T3 (da) | Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf | |
MA47440A (fr) | Sulfonylurées, composés apparentés, et leur utilisation | |
DK3452448T3 (da) | Modulatorer af den integrerede stressvej | |
MA45613A (fr) | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique | |
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
DK3558278T3 (da) | Flydende cannabinoidsammensætning | |
DK3319963T3 (da) | Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer | |
MA47609A (fr) | Anticorps anti-il31 à usage vétérinaire | |
MA47311A (fr) | Anticorps anti-tgf-bêta et leur utilisation | |
MA50440A (fr) | Imidazopyridinamides substituées et leur utilisation | |
MA51224A (fr) | Composés de sulfonamide et leur utilisation | |
MA48583A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
DK3749669T3 (da) | Ahr-modulatorer |